Media coverage about Juniper Pharmaceuticals (NASDAQ:JNP) has been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Juniper Pharmaceuticals earned a media sentiment score of 0.24 on Accern’s scale. Accern also gave media stories about the specialty pharmaceutical company an impact score of 46.8666957028664 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
JNP has been the subject of a number of analyst reports. BMO Capital Markets raised shares of Juniper Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $31.00 to $34.00 in a research report on Friday, July 14th. ValuEngine downgraded shares of Juniper Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. HC Wainwright reissued a “hold” rating on shares of Juniper Pharmaceuticals in a research report on Monday, May 15th. Finally, Roth Capital set a $12.00 price objective on shares of Juniper Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, May 6th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $17.58.
Shares of Juniper Pharmaceuticals (JNP) traded up 1.11% on Friday, hitting $4.55. 12,357 shares of the stock were exchanged. Juniper Pharmaceuticals has a 1-year low of $3.65 and a 1-year high of $6.40. The stock has a market cap of $49.34 million, a price-to-earnings ratio of 5.88 and a beta of 0.28. The stock’s 50-day moving average is $4.88 and its 200-day moving average is $4.71.
Juniper Pharmaceuticals (NASDAQ:JNP) last announced its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.10. Juniper Pharmaceuticals had a net margin of 13.94% and a return on equity of 21.49%. The firm had revenue of $13.96 million for the quarter, compared to the consensus estimate of $11.84 million. Analysts forecast that Juniper Pharmaceuticals will post ($0.51) earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This news story was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://stocknewstimes.com/2017/08/18/juniper-pharmaceuticals-jnp-given-media-sentiment-rating-of-0-24-updated.html.
Juniper Pharmaceuticals Company Profile
Juniper Pharmaceuticals, Inc is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product.
Receive News & Ratings for Juniper Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
